Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2023 09:37 ET | Source: Advaxis, Inc.

Advaxis and Ayala Pharmaceuticals Complete Merger

REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and...
January 12, 2023 08:04 ET | Source: Advaxis, Inc.

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of six...
October 19, 2022 06:30 ET | Source: Advaxis, Inc.

Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in...
September 12, 2022 18:40 ET | Source: Advaxis, Inc.

Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update

Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer Cash runway extends...
June 29, 2022 08:00 ET | Source: Advaxis, Inc.

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level MONMOUTH JUNCTION, N.J., June 29,...
June 08, 2022 08:00 ET | Source: Advaxis, Inc.

Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical...
June 03, 2022 16:05 ET | Source: Advaxis, Inc.

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
May 26, 2022 17:00 ET | Source: Advaxis, Inc.

Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA®...
April 27, 2022 10:00 ET | Source: Advaxis, Inc.

Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...
April 08, 2022 08:00 ET | Source: Advaxis, Inc.

Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with...